Description:
A drug used with granulocyte-macrophage colony-stimulating factor (GM-CSF) to treat children aged 1 year and older and adults with certain types of high-risk neuroblastoma in the bone or bone marrow that came back or did not get better with other treatment. It is also being studied in the treatment of other types of cancer. Danyelza binds to a substance called GD2, which is found on some types of cancer cells. Danyelza may block GD2 and help the immune system kill cancer cells. It is a type of monoclonal antibody. Also called naxitamab.
